» Articles » PMID: 27107797

Microglial Phenotypes in Parkinson's Disease and Animal Models of the Disease

Overview
Journal Prog Neurobiol
Specialty Neurology
Date 2016 Apr 25
PMID 27107797
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Over the last decade the important concept has emerged that microglia, similar to other tissue macrophages, assume different phenotypes and serve several effector functions, generating the theory that activated microglia can be organized by their pro-inflammatory or anti-inflammatory and repairing functions. Importantly, microglia exist in a heterogenous population and their phenotypes are not permanently polarized into two categories; they exist along a continuum where they acquire different profiles based on their local environment. In Parkinson's disease (PD), neuroinflammation and microglia activation are considered neuropathological hallmarks, however their precise role in relation to disease progression is not clear, yet represent a critical challenge in the search of disease-modifying strategies. This review will critically address current knowledge on the activation states of microglia as well as microglial phenotypes found in PD and in animal models of PD, focusing on the expression of surface molecules as well as pro-inflammatory and anti-inflammatory cytokine production during the disease process. While human studies have reported an elevation of both pro- or anti-inflammatory markers in the serum and CSF of PD patients, animal models have provided insights on dynamic changes of microglia phenotypes in relation to disease progression especially prior to the development of motor deficits. We also review recent evidence of malfunction at multiple steps of NFκB signaling that may have a causal interrelationship with pathological microglia activation in animal models of PD. Finally, we discuss the immune-modifying strategies that have been explored regarding mechanisms of chronic microglial activation.

Citing Articles

Chemically Induced Senescence Prompts Functional Changes in Human Microglia-Like Cells.

Armanville S, Tocco C, Haj Mohamad Z, Clarke D, Robitaille R, Drouin-Ouellet J J Immunol Res. 2025; 2025:3214633.

PMID: 40041406 PMC: 11876530. DOI: 10.1155/jimr/3214633.


The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases.

Sarallah R, Jahani S, Khaboushan A, Moaveni A, Amiri M, Zolbin M Brain Behav Immun Health. 2025; 43():100932.

PMID: 39834554 PMC: 11743895. DOI: 10.1016/j.bbih.2024.100932.


Aging and MPTP Sensitivity Depend on Molecular and Ultrastructural Signatures of Astroglia and Microglia in Mice Substantia Nigra.

Abhilash P, Bharti U, Rashmi S, Philip M, Raju T, Kutty B Cell Mol Neurobiol. 2025; 45(1):13.

PMID: 39833644 PMC: 11753320. DOI: 10.1007/s10571-024-01528-8.


Modulation of the central nervous system immune response and neuroinflammation via Wnt signaling in health and neurodegenerative diseases.

Fang K Ibrain. 2024; 10(4):462-476.

PMID: 39691422 PMC: 11649390. DOI: 10.1002/ibra.12185.


Targeting Ferroptosis in Parkinson's Disease: Mechanisms and Emerging Therapeutic Strategies.

Zhou M, Xu K, Ge J, Luo X, Wu M, Wang N Int J Mol Sci. 2024; 25(23).

PMID: 39684753 PMC: 11641825. DOI: 10.3390/ijms252313042.


References
1.
Garcia-Esparcia P, Llorens F, Carmona M, Ferrer I . Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson's disease brain is region dependent. Brain Pathol. 2014; 24(6):584-98. PMC: 8029304. DOI: 10.1111/bpa.12137. View

2.
Ramonet D, Daher J, Lin B, Stafa K, Kim J, Banerjee R . Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011; 6(4):e18568. PMC: 3071839. DOI: 10.1371/journal.pone.0018568. View

3.
Armentero M, Levandis G, Nappi G, Bazzini E, Blandini F . Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol Dis. 2006; 24(3):492-505. DOI: 10.1016/j.nbd.2006.08.016. View

4.
Fox S, Henry B, Hill M, Crossman A, Brotchie J . Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2002; 17(6):1180-7. DOI: 10.1002/mds.10289. View

5.
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M . Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010; 5(1):e8784. PMC: 2808388. DOI: 10.1371/journal.pone.0008784. View